Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.AVEO Oncology and Biodesix to discontinue CyFi-2 study of ficlatuzumab in AML in response to public health crisis
AVEO Oncology and Biodesix to discontinue CyFi-2 study of ficlatuzumab in AML in response to public health crisis. (Credit: PublicDomainPictures from Pixabay)